id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-D-0461-0068,FDA,FDA-2009-D-0461,Novartis Pharmaceuticals Corporation (NPC) - Supplement,Other,SUP-Supplement,2010-10-21T04:00:00Z,2010,10,2010-10-21T04:00:00Z,,2013-07-27T23:35:13Z,,0,0,0900006480b73fde
FDA-2009-D-0461-0040,FDA,FDA-2009-D-0461,Risk Evaluation and Mitigation Strategies; Notice of Public Meeting; Reopening of Comment Period,Notice,NM-Notice of Meeting,2010-06-17T04:00:00Z,2010,6,2010-06-17T04:00:00Z,2010-09-01T03:59:59Z,2010-10-29T01:10:10Z,2010-14547,0,0,0900006480b041b2